Federico Rotolo

Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

Siddhartha Devarakonda, Federico Rotolo, Ming‐Sound Tsao et al. · Journal of Clinical Oncology · 2018 · 297 citations · Full text

Medicine, Molecular Genetics, Oncology +17

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

M. Bagot, Pierluigi Porcu, Anne Marie‐Cardine et al. · The Lancet Oncology · 2019 · 157 citations · Full text

Medicine, Hematology, Oncology +13

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani et al. · Journal of Hematology & Oncology · 2021 · 85 citations · Full text

Medicine, Oncology, Pharmacology +15

Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

Roger B. Cohen, Jessica R. Bauman, Sébastien Salas et al. · Journal of Clinical Oncology · 2020 · 40 citations

Medicine, Immunology, Pharmacology +17

Identification of biomarker‐by‐treatment interactions in randomized clinical trials with survival outcomes and high‐dimensional spaces

Nils Ternès, Federico Rotolo, Georg Heinze et al. · Biometrical Journal · 2016 · 39 citations · Full text

Public Health, Biomedical Sciences, Biostatistics +15